Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice
- 1 June 2011
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (16), 2266-2272
- https://doi.org/10.1200/jco.2010.34.1248
Abstract
Purpose The aims of this study were to compare the approaches of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in the evaluation and approval of new anticancer indications and to identify possible clinical implications associated with these differences. Methods Information on the European Union therapeutic indications for the cohort of anticancer drugs was extracted from the European Public Assessment Reports and from the FDA review reports. Results Overall, 42 anticancer drugs were approved by EMA between 1995 and 2008, corresponding to a total of 100 indications. In 47 of 100 indications, a difference was found. For 19 of these 47 indications, the difference was that one agency approved an indication, whereas the other agency did not. For the remaining 28 indications, the same indication was approved by both of the agencies and differences were evaluated through an algorithm; in 10 cases, discrepancies in therapeutic indications between EMA and FDA were considered cli...Keywords
This publication has 8 references indexed in Scilit:
- Regulatory Action on Rosiglitazone by the U.S. Food and Drug AdministrationNew England Journal of Medicine, 2010
- Insiders criticise FDA's decision not to withdraw rosiglitazoneBMJ, 2010
- Transparency at the Food and Drug AdministrationNew England Journal of Medicine, 2010
- Europe's opportunity to open up drug regulationBMJ, 2010
- Therapeutic indications in oncology: Emerging features and regulatory dynamicsEuropean Journal Of Cancer, 2010
- Paying for Drug Approvals — Who's Using Whom?New England Journal of Medicine, 2007
- The drug lag: An update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987Clinical Pharmacology & Therapeutics, 1989